|
|
|
| Effects of Palmatine on Proliferation Apoptosis and Cisplatin Sensitivity in BRAF/KRAS Mutant Non-Small Cell Lung Cancer Cells |
| HUANG Liang, et al |
| The Affiliated Hospital of Chengde Medical University, Hebei Chengde 067000, China |
|
|
|
|
Abstract Objective: To investigate the protective effect and mechanism of Palmatine on proliferation, apoptosis and cisplatin sensitivity in BRAF/KRAS mutant non-small cell lung cancer cells (NSCLC). Methods: The BRAF/KRAS mutant NSCLC cell line A549 was used as the research subject, and the effects of Palmatine on cell proliferation, apoptosis and cisplatin sensitivity were detected by thiazolyl blue method and flow cytometry, respectively. Western blotting was used to detect the expression of Bcl-2 and PARP protein. Results: Compared with the control group, the proliferation viability, Bcl-2 and PARP protein expression were significantly lower and the apoptosis rate was significantly higher in the 1 μmol/L, 5 μmol/L and 10 μmol/L groups (P<0.05). Compared with the control group, the proliferation viability, Bcl-2 and PARP protein expression were significantly reduced and the apoptosis rate was significantly increased in the palmatine and cisplatin groups (P<0.05); compared with the cisplatin group, the proliferation viability, Bcl-2 and PARP protein expression were further reduced and the apoptosis rate was further increased in the cisplatin+palmatine group (P<0.05). Conclusion: Palmatine can inhibit the proliferation of BRAF/KRAS mutant NSCLC cells, induce apoptosis, and enhance the sensitivity of cisplatin.
|
|
|
|
|
|
[1] Jonna S,Subramaniam DS.Molecular diagnostics and targeted therapies in non-small cell lung cancer (NSCLC):an update[J].Discov Med,2019,27(148):167-170.
[2] Negrao MV,Raymond VM,Lanman RB,et al.Molecular landscape of BRAF-mutant NSCLC reveals an association between clonality and driver mutations and identifies targetable non-V600 driver mutations[J].Thorac Oncol,2020,15(10):1611-1623.
[3] Uras IZ,Moll HP,Casanova E.Targeting KRAS mutant non-small-cell lung cancer:past,present and future[J].Int Mol Sci,2020,21(12):4325.
[4] Long J,Song J,Zhong L,et al.Palmatine:a review of its pharmacology,toxicity and pharmacokinetics[J].Biochimie,2019,162:176-184.
[5] Johnson-Ajinwo OR,Richardson A,Li WW.Palmatine from unexplored rutidea parviflora showed cytotoxicity and induction of apoptosis in human ovarian cancer cells[J].Toxins (Basel),2019,11(4):237.
[6] Leonetti A,Facchinetti F,Rossi G,et al.BRAF in non-small cell lung cancer (NSCLC):Pickaxing another brick in the wall[J].Cancer Treat Rev,2018,66:82-94.
[7] Arbour KC,Riely GJ.Systemic Therapy for locally advanced and metastatic non-small cell lung cancer: a review[J].JAMA,2019,322(8):764-774.
[8] Liu X,Zhang Y,Wu S,et al.Palmatine induces G2/M phase arrest and mitochondrial-associated pathway apoptosis in colon cancer cells by targeting AURKA[J].Biochem Pharmacol,2020,175:113933.
[9] 耿帅,郭宏举.多西他赛联合顺铂治疗晚期非小细胞肺癌有效性和安全性的Meta分析[J].河北医学,2020,26(4):620-625.
[10] 张媛媛,马静,何会娜,等.PTEN和Notch1在非小细胞肺癌组织中表达及临床意义[J].河北医学,2021,27(10):1637-1643.
[11] Lok BH,Gardner EE,Schneeberger VE,et al.PARP inhibitor activity correlates with SLFN11 expression and demonstrates synergy with temozolomide in small cell lung cancer[J].Clin Cancer Res,2017,23(2):523-535. |
|
|
|
2022, Vol. 28 
